EP Winer

774 total citations
50 papers, 563 citations indexed

About

EP Winer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, EP Winer has authored 50 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in EP Winer's work include Cancer Treatment and Pharmacology (24 papers), Advanced Breast Cancer Therapies (17 papers) and HER2/EGFR in Cancer Research (15 papers). EP Winer is often cited by papers focused on Cancer Treatment and Pharmacology (24 papers), Advanced Breast Cancer Therapies (17 papers) and HER2/EGFR in Cancer Research (15 papers). EP Winer collaborates with scholars based in United States, United Kingdom and France. EP Winer's co-authors include JA Ligibel, J. A. Sparano, Craig A. Bunnell, Andreas Schneeweiß, Sherene Loi, Hiroji Iwata, Luciana Molinero, Peter Schmid, Anh Nguyen Duc and Sylvia Adams and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

EP Winer

46 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
EP Winer United States	11	483	173	136	85	74	50	563
Monica Milano Italy	10	311 0.6×	176 1.0×	138 1.0×	60 0.7×	83 1.1×	22	489
Petr Krivorotko Russia	8	213 0.4×	94 0.5×	132 1.0×	71 0.8×	76 1.0×	91	415
Chang Shu Wang Canada	12	241 0.5×	146 0.8×	173 1.3×	37 0.4×	47 0.6×	15	565
Susanne Muehlbauer Switzerland	4	708 1.5×	151 0.9×	98 0.7×	61 0.7×	284 3.8×	10	866
Nello Salesi Italy	11	314 0.7×	60 0.3×	81 0.6×	79 0.9×	36 0.5×	27	439
Minsig Choi United States	14	360 0.7×	104 0.6×	134 1.0×	60 0.7×	58 0.8×	28	549
Sarah Sammons United States	16	466 1.0×	168 1.0×	399 2.9×	48 0.6×	41 0.6×	92	706
Karel Cwiertka Czechia	10	247 0.5×	108 0.6×	123 0.9×	25 0.3×	40 0.5×	45	436
J. De Waal Germany	5	331 0.7×	210 1.2×	98 0.7×	22 0.3×	29 0.4×	13	425
Aiko Nagayama Japan	9	274 0.6×	100 0.6×	92 0.7×	27 0.3×	97 1.3×	27	394

Countries citing papers authored by EP Winer

Since Specialization

Citations

This map shows the geographic impact of EP Winer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by EP Winer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites EP Winer more than expected).

Fields of papers citing papers by EP Winer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by EP Winer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by EP Winer. The network helps show where EP Winer may publish in the future.

Co-authorship network of co-authors of EP Winer

This figure shows the co-authorship network connecting the top 25 collaborators of EP Winer. A scholar is included among the top collaborators of EP Winer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with EP Winer. EP Winer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bachelot, Thomas, NU Lin, Sara A. Hurvitz, et al.. (2020). 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases. Annals of Oncology. 31. S359–S360. 9 indexed citations

Goel, Shom, et al.. (2019). Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer. Cancer Research. 79(4_Supplement). P6–18. 1 indexed citations

Cortés, Javier, Oleg Lipatov, S. Im, et al.. (2019). KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Annals of Oncology. 30. v859–v860. 95 indexed citations

Hortobagyi, G. N., Steven Shak, EP Winer, et al.. (2019). Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study. Cancer Research. 79(4_Supplement). P3–11. 9 indexed citations

Matulonis, U., Lewis C. Cantley, C. Whalen, et al.. (2013). Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC). Cancer Research. 73(24_Supplement). OT1–4.

Perez, EA, et al.. (2012). Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study. Cancer Research. 72(24_Supplement). PD10–4. 4 indexed citations

Tolaney, SM, Howard A. Burris, Elaina M. Gartner, et al.. (2011). P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.. Cancer Research. 71(24_Supplement). P1–17. 1 indexed citations

Sepucha, Karen, J Hirshfield-Bartek, Susan L. Troyan, et al.. (2011). P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer.. Cancer Research. 71(24_Supplement). P4–11. 2 indexed citations

Ligibel, JA, HJ Burstein, KD Miller, et al.. (2011). OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.. Cancer Research. 71(24_Supplement). OT3–2. 3 indexed citations

10.

Partridge, AH, et al.. (2010). Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial. Cancer Research. 70(24_Supplement). P4–9. 3 indexed citations

11.

Isakoff, SJ, Jennifer Savoie, Joan D. Beckman, et al.. (2009). A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.. Cancer Research. 69(2_Supplement). 906–906. 1 indexed citations

12.

Broadwater, Gloria, Paula N. Friedman, D. A. Berry, et al.. (2009). Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.. Cancer Research. 69(2_Supplement). 6046–6046. 1 indexed citations

13.

Rugo, HS, LA Carey, Erica L. Mayer, et al.. (2009). Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001.. Cancer Research. 69(2_Supplement). 6048–6048. 1 indexed citations

14.

Muss, H. B., DA Berry, C. Cirrincione, et al.. (2006). Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. Journal of Clinical Oncology. 24(18_suppl). 559–559.

15.

Berry, D. A., C. Cirrincione, R. B. Livingston, et al.. (2005). Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Journal of Clinical Oncology. 23(16_suppl). 620–620. 11 indexed citations

16.

Seidman, A. D., Gloria Broadwater, L. G. Dressler, et al.. (2005). Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840. Journal of Clinical Oncology. 23(16_suppl). 558–558. 2 indexed citations

17.

Ligibel, JA & EP Winer. (2002). Trastuzumab/chemotherapy combinations in metastatic breast cancer. Seminars in Oncology. 29(3). 38–43. 67 indexed citations

18.

Sparano, J. A. & EP Winer. (2001). Liposomal anthracyclines for breast cancer. Seminars in Oncology. 28(4 Suppl 12). 32–40. 42 indexed citations

19.

Burstein, HJ, Lyndsay N. Harris, Carolyn M. Kaelin, et al.. (2001). Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage breast cancer. European Journal of Cancer. 37. S146–S146. 5 indexed citations

20.

Demark‐Wahnefried, Wendy, et al.. (1997). Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.. Rehabilitation Oncology. 15(3). 21–21. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact